Clinical Trial Update: Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure [Phase 1]

View source ↗

Summary

Clinical trial update announcing a Phase 1 study of EXG34217 in patients with telomere biology disorders and bone marrow failure, currently active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Marrow Failure
• Telomere Biology Disorders

Drugs mentioned

• EXG34217

Snippet

Sponsor: Elixirgen Therapeutics, Inc. | Conditions: Telomere Shortening, Bone Marrow Failure | Phase 1 | Status: ACTIVE_NOT_RECRUITING